Completed PHASE2 INTERVENTIONAL NCT00052052

An Open-Label Study of the Safety and Efficacy of Subcutaneous Recombinant Interferon-Gamma 1b (IFN-Gamma 1b) in Patients With Idiopathic Pulmonary Fibrosis (IPF)

An Open-Label Study of the Safety and Efficacy of Subcutaneous Recombinant Interferon Gamma-1b in Patients With Idiopathic Pulmonary Fibrosis.

Sponsor: InterMune

Conditions Lung Disease Pulmonary Fibrosis

Interventions interferon-gamma 1b

Updated 5 times since 2017 Last updated: Nov 2, 2007 Started: Sep 30, 2002 Completion: Sep 30, 2004

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00052052, this PHASE2 trial focuses on Lung Disease and Pulmonary Fibrosis and remains completed. Sponsored by InterMune, it has been updated 5 times since 2002, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Sep 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

InterMune

Data source: InterMune

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Seattle, United States